U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07543822) titled '24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs' on April 15.
Brief Summary: The study will enroll participants 2 months of age up to 30 years of age. The purpose of this study is to assess the effectiveness and safety of Alpelisib (the "Study Drug") in patients with PIK3CA/TIE-2/TEK pathway driven vascular anomalies (VA). Alpelisib has been approved by the U.S. Food and Drug Administration (FDA) for treating adults and children with certain types of breast cancer. Its use in this study is considered experimental because FDA has not approved the study drug for treating people with VAs.
Study participation will last for up to ...